Filing Flows › Gilead Sciences (GILD) › Q3 2026
Gilead Sciences (GILD) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 30, 2026
Gilead Sciences (GILD) reported revenue of $8.3B for the third quarter 2026 (Q3 2026), +7% from a year earlier and +6% from the quarter before. Operating margin was 41.7%, net earnings $2.4B (29.3% of revenue).
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.3B | +6% | +7% |
| Operating profit | $3.5B | — | +4% |
| Net earnings | $2.4B | — | -20% |
| Operating cash flow | $5.0B | +41% | +23% |
| Free cash flow | $4.8B | — | +21% |
What changed
Revenue was $8.3B in Q3 2026, up 7% year over year and up 6% from the previous quarter. Biktarvy was the largest line at 49% of revenue. Biktarvy added $0.37B year over year (up 10%), 70% of the total change. Total Cell Therapy declined 18%.
Operating profit was $3.5B, a 41.7% margin (down 1.1 points year over year). Of the extra revenue versus Q3 2025, 25% reached operating profit, below the 43% margin then. Total costs grew 9% against revenue growth of 7%. The fastest-growing cost line was SG&A (+21%). Net earnings were $2.4B, down 20% year over year. The effective tax rate was 20.7%.
Operating cash flow was $5.0B (up 23% year over year), 207% of net earnings. Non-cash charges added back $0.13B of depreciation and $0.23B of share-based compensation. Working capital and other items added $2.2B. After purchases of property, plant and equipment ($0.24B), free cash flow as the company reports it was $4.8B.
Questions
What was Gilead Sciences' revenue in the third quarter 2026?
Gilead Sciences (GILD) reported revenue of $8.3B for the third quarter 2026 (Q3 2026), +7% from a year earlier and +6% from the quarter before.
Was Gilead Sciences profitable in the third quarter 2026?
Operating profit was $3.5B (41.7% of revenue) and net earnings $2.4B.
Source: Gilead Sciences 10-Q on SEC EDGAR.